Anupam Rasayan Expands Global Footprint with $150M US Acquisition

Anupam Rasayan India Ltd. announced the successful completion of its acquisition of US-based Jayhawk Fine Chemicals Corporation for approximately US$150 million on February 27, 2026.
The financing comprises US$109 million from issued shares and US$41 million via debt, funded by Altis XII Pte. Ltd. and Axis Bank.

Reader Takeaway: Global reach expands with US acquisition; elevated working capital remains a concern.

What just happened (today’s filing)

Anupam Rasayan India Ltd. has finalized the acquisition of 100% of Jayhawk Fine Chemicals Corporation, a US-based specialty chemical company. The total purchase consideration was approximately US$150 million.

This strategic transaction was financed through a combination of US$109 million in Class B shares and US$41 million in debt. Key funding partners included Altis XII Pte. Ltd. for US$129 million and Axis Bank for US$21 million.

The acquisition is projected to be Earnings Per Share (EPS) accretive for Anupam Rasayan, reinforcing its established global footprint and enhancing its specialty chemicals platform.

Why this matters

This acquisition marks Anupam Rasayan's entry into direct onshore manufacturing in the United States. It aligns with the company's long-term strategy to expand its global CDMO presence and establish a stronger foothold in the US and global specialty chemicals market.

The move positions Anupam Rasayan closer to end-user applications by manufacturing key N-1 molecules for critical sectors such as electronics, semiconductors, aviation, and performance materials. It aims to create a robust, integrated platform with complementary chemistries and deeper customer engagement.

The backstory (grounded)

Anupam Rasayan, a specialty chemicals manufacturer established in 2003 and listed in 2021, has been steadily building its capabilities. The company previously expanded its operations through the acquisition of a significant stake in Tanfac Industries in May 2022, a move that bolstered its backward integration in fluorination chemistry.

Strategically, Anupam Rasayan has focused on custom synthesis (CSM) and expanding its global CDMO presence, aiming to move up the value chain. Recent financial reports indicate strong growth, with Q3 FY26 consolidated revenue reaching INR 5,145 million (+33% YoY), contributing to a 9-month consolidated revenue of INR 17,297 million (+84% YoY).

What changes now

• Enhanced Global Presence: Anupam Rasayan gains immediate manufacturing capabilities and a strategic presence in the key US market.
• Access to New Applications: The company will now be involved in manufacturing N-1 molecules for high-growth sectors like electronics and semiconductors.
• Strengthened Platform: The acquisition is expected to create a more integrated specialty chemicals platform with broader chemistry capabilities.
• EPS Accretion: The deal is anticipated to positively contribute to Anupam Rasayan's earnings per share from the outset.

Risks to watch

Elevated working capital challenges remain a significant concern for Anupam Rasayan. Gross current assets were around 646 days as of March 2025, though the company is working towards improvement.

Following the acquisition announcement, credit rating agencies CRISIL and India Ratings placed Anupam Rasayan on 'Rating Watch with Negative Implications' due to concerns surrounding acquisition funding and ongoing working capital issues.

Additionally, as of the December 2025 quarter, approximately 15.99% of promoter holdings were pledged.

Peer comparison

Anupam Rasayan's acquisition of a US manufacturing base positions it more directly against global players and its Indian peers like SRF Ltd. and Navin Fluorine International Ltd., who also have significant international operations and focus on advanced chemistry. While Anupam's peers like Deepak Nitrite and Vinati Organics continue to show strong growth and resilience, Anupam's move into direct US manufacturing differentiates its global expansion strategy, although it faces scrutiny over working capital management and funding, a contrast to some peers with more stable financial metrics.

Context metrics (time-bound)

• Anupam Rasayan's Return on Equity (ROE) was 3.32% and Return on Capital Employed (ROCE) was 7.33% over the last three years (FY23-FY25).
• Gross Current Assets (GCAs) stood at approximately 646 days as of March 2025, showing an improvement from prior periods with a target to reduce further.

What to track next

• Integration Success: Monitor the seamless integration of Jayhawk Fine Chemicals into Anupam Rasayan's operations and management structure.
• Financial Performance: Observe how the acquisition impacts Anupam Rasayan's EPS, revenue growth, and profitability metrics.
• Working Capital Management: Track the company's progress in reducing working capital days and alleviating pressure on its liquidity.
• Rating Agency Actions: Watch for any rating upgrades or downgrades from CRISIL and India Ratings as the acquisition impact and working capital situation evolve.
• Synergy Realization: Assess the realization of expected synergies in terms of cross-selling opportunities, technology transfer, and market penetration.